Cellou Binani/AFP/Getty Images

In a small trial, an experimental vaccine protected 100 percent of people at high risk for Ebola. But more data are needed to figure out exactly how well the vaccine works. The study was published last week in the journal The Lancet.

Read more at NPR.org.

Sean Hawkey

The trial of the VSV-EBOV vaccine was called Ebola ça Suffit — French for “Ebola that’s enough.” Researchers say it’s both effective and quick, with no new Ebola cases 6 days after vaccination. The findings were published in The Lancet medical journal on Friday.

Read more at NPR.org.

Ira Gay Sealy/Denver Post via Getty Images

It took 15 years and 250 million vaccines, but this week, health authorities officially declared North America and South America free of rubella — a virus that can cause severe birth defects.

Read more at NPR.org.